Resources

View and download resources that can help before, during, and after you prescribe Trulance
FOR
HCPs FOR
PATIENTS

Trulance resources for healthcare providers

Download Copay Cards

Eligible,a commercially insured patients may have a copay as low as $25 for up to a 90-day supply.

Download Copay Card

Get Trulance Samples

Help give your appropriate patients samples of Trulance.

Get Samples

Speak With a Rep

Call 1-800-321-4576 to speak with a representative and learn more about Trulance.

ICD-10 Codesb for Trulance

Diagnostic code for patients with IBS-C: K58.1

Diagnostic code for patients with CIC: K59.04

If you work with CoverMyMeds, you can start a
prior authorization for Trulance to assist with approval

84.3%

approval rate for commercially insured patients1,c

81.3%

approval rate for Medicare Part D patients1,c

To start a prior authorization, call 1-866-452-5017 or visit CoverMyMeds.com.

Prior Authorization Guide

Get tips on securing approval for prior authorizations.

Download the Guide

Sample Letter of Medical Necessity

A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

Download

Trulance Patient Experiences

Watch patients share their experiences with Trulance.

Watch Stephanie’s Story Watch Stacey’s Story

Trulance Patient Profiles

Learn how Trulance can benefit a typical patient who you may see in your practice.

View Patient Profiles

Mechanism of Action Video

Learn about how Trulance is the only structural analog of the human peptide uroguanylin.2-4

Explore Trulance MOA

Trulance Commercial

Watch the promotional video highlighting treatment with Trulance and elevating the patient experience.

Watch Commercial

Trulance resources for patients

savings card

Trulance Savings Card

Help your eligible,a commercially insured patients save on their Trulance prescription.

Download Copay Card

Trulance Patient Brochure

Help your patients understand what to expect with Trulance with a downloadable patient brochure.

English

aPatient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash–paying patients. To qualify for this offer, the patient’s out-of-pocket expense must be a minimum of $25 per prescription. Maximum savings limit applies; patient out-of-pocket expense may vary. Must be 18 years of age or older and under the age of 65 to participate in the program. This offer is good only in the US and Puerto Rico and is void where prohibited by law. Offer is valid for up to 12 prescription fills per year. Expires 12/31/ .

bThe ICD-10 codes and all other patient-access–related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

cAs of 12/2022. Submission is not a guarantee of coverage or payment. Payer coverage subject to change without notice.

Sign up to receive emails and stay up to
date on Trulance
Show More
Indication

Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice administration of a single oral dose of plecanatide caused deaths due to dehydration. Use of Trulance should be avoided in patients 6 years to less than 18 years of age. The safety and efficacy of Trulance have not been established in pediatric patients less than 18 years of age.

 

Contraindications
  • Trulance is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • Trulance is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Risk of Serious Dehydration in Pediatric Patients
  • Trulance is contraindicated in patients less than 6 years of age. The safety and effectiveness of Trulance in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid secretion as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than older patients to develop severe diarrhea and its potentially serious consequences.
  • Use of Trulance should be avoided in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young mice and the lack of clinical safety and efficacy data in pediatric patients, use of Trulance should be avoided in patients 6 years to less than 18 years of age.
Diarrhea
  • Diarrhea was the most common adverse reaction in the four placebo-controlled clinical trials for CIC and IBS-C. Severe diarrhea was reported in 0.6% of Trulance-treated CIC patients, and in 1% of Trulance-treated IBS-C patients.
  • If severe diarrhea occurs, the health care provider should suspend dosing and rehydrate the patient.
Adverse Reactions
  • In the two combined CIC clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (5% vs 1% placebo).
  • In the two combined IBS-C clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (4.3% vs 1% placebo).

Please also see the full Prescribing Information, including BOXED Warning, for additional risk information.